[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"viral-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:viral-infections":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,86,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100465142","emergency-pwas-in-respiratory-infectious-disease-100465142",false,"NCT05336851","Emergency PWAS in Respiratory Infectious Disease","Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)","Inclusion Criteria:\n\nPatients eligible for enrolment include:\n\nWith reference to previous inclusion criteria are:\n\n* Adults ≥18 years of age; AND\n* Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\\*; AND\n* Informed consent.\n\nNote: scaRID is defined according to ALL three criteria:\n\n1. Community acquired (not hospitalised for \\\u003C28 days); AND\n2. Acute infection (defined as symptom onset \\\u003C8 days and any ONE of reported fever or chills or aural temperature \\>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND\n3. Probable respiratory infection - According to any ONE of:\n\n   1. new cough or new sputum production or\n   2. chest pain or\n   3. dyspnoea or\n   4. tachypnoea or\n   5. abnormal lung examination or\n   6. respiratory failure; or\n   7. physician's judgment (presenting with systemic or gastrointestinal symptoms).\n\nControl subjects will be drawn from two groups:\n\n* The worried well - adult patients with a National Early Warning Score (NEWS) \\\u003C3 and a temperature \\\u003C37.5°C.\n* Relatives or accompanying friends with no acute illness.\n\nExclusion Criteria:\n\n* Refusal of consent;\n* Recent hospitalisation (\\\u003C28 days);\n* Enrolled in another clinical trial\n* Cellulitis;\n* Skin or orthopaedic infections;\n* Urinary tract infection;\n* Acute abdominal sepsis;\n* Sexual transmitted disease;\n* Human immunodeficiency virus (HIV) infection;\n* Immunocompromised\u002Fpotential neutropenic fever;\n* Solid organ or haematopoietic stem-cell transplant within the previous 90 days;\n* Active graft-versus-host disease or bronchiolitis obliterans;\n* Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;\n* Stroke;\n* Toxidrome;\n* Non-organic acute psychosis.",true,"ALL","18 Years","100 Years",{"count":21,"type":22},2000,"ESTIMATED","1 Year","OBSERVATIONAL","Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).\n\nPhase 1\n\n1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2\n2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics",[27,28,29,30,31,32,33,34],"Viral Infections","Bacterial Infections","Fungal Infections","Mixed Infection","Mycobacterium Infection","Infection of Uncertain Aetiology","Pneumonia","Sepsis",[36,37,38,39,40],"Biobank","Diagnostics and Prognostics","Emergency Medicine","Multiomics and Panoromics","Respiratory Infectious Disease","RECRUITING","2026-05-07",{"date":44,"type":45},"2026-05-12","ACTUAL",{"date":47,"type":45},"2023-04-11",{"date":49,"type":22},"2028-05-01",{"name":51,"class":52},"The University of Hong Kong","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":53},"100595301","early-discontinuation-of-antibiotic-therapy-in-elderly-patients-hospitalized-for-a-viral-infection-100595301","NCT07030673","Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection","ABUSIV","Inclusion Criteria:\n\n* Patients ≥ 65 years affiliated to a social security scheme\n* Hospitalized for a lower respiratory infection defined as:\n\n  * the presence of 2 of the following 4 signs:\n  * hyperthermia \\>38°C,\n  * hyperleukocytosis ≥12000 or ≤4000,\n  * purulent aspirations\u002Fsputum,\n  * rales on pulmonary auscultation indicating parenchymal damage\n  * associated with a pulmonary image (standard X-ray, CT scan or ultrasound)\n* Microbiological diagnostic sample taken within 48 hours\n* Informed consent of the patient or their representative\n\nExclusion Criteria:\n\n* Hospitalization planned for \\\u003C 48 hours or transfer planned to another center within 7 days\n\n  * Patient in septic shock,\n  * Febrile aplasia\n  * Absence of diagnostic microbiological sampling (\\> 48 hours after admission)\n  * Moribund patient,\n  * Death expected within the week\n  * Inhalation proven by endoscopy or eyewitness\n  * Purulent pleurisy, lung abscess, or other concomitant bacterial infection requiring antibiotic therapy.","65 Years",{"count":63,"type":22},256,"INTERVENTIONAL",[66],"NA","Among winter respiratory viruses, influenza is the most common and therefore responsible for the highest mortality, but parainfluenza and RSV viruses have an even higher risk of mortality (1.6 to 1.9 times), this toll being paid mainly by the elderly and co-morbid population. Futhermore, SARS-Cov2 will probably become endemic and\u002For epidemic with the same targets of fragile patients. These viral infections are serious, however a bacterial co-infection worsens the prognosis even more: excess risk of mortality = 2.6, 95% CI \\[1.9-3.7\\].\n\nAlthough rare, these co-infections are the subject of a prescription of antibiotics in more than 50% of influenza infections or other serious viral infections. Mainly due to this excess risk of mortality associated with the difficulty of diagnosing these co-infections.\n\nProper antibiotic use requires preventing this misuse and its harmful consequences in the short and long term at all costs. It is therefore imperative to have solid (grade A) evidence showing that antibiotic therapy in viral infections is not only futile but also potentially harmful.",[69,70,27,71],"Elderly","Antibiotics Overuse","PCR Multiplex",[73,74,75,76],"viral infections","elderly","antibiotics overuse","PCR multiplex","2026-01-15",{"date":79,"type":45},"2026-01-16",{"date":81,"type":45},"2025-02-14",{"date":83,"type":22},"2027-06",{"name":85,"class":52},"Centre Hospitalier Universitaire, Amiens",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":94,"enrollmentInfo":95,"targetDuration":97,"studyType":24,"phases":4,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100612162","respiratory-infections-in-young-children-100612162","NCT07249996","Respiratory Infections in Young Children","Respiratory Infections in Young Children in Colombia and Panamá: Epidemiology, Interactions, and Long-term Consequences.","MINERVAL","Inclusion Criteria:\n\n* Newborns younger than 29 days of life, with or without pre-existing conditions\n* Infants whose parent(s) or guardian(s) are available for telephone contact for the duration of the study, and do not intend to relocate outside of the study area, to ensure adherence to RTI and in-person visits.\n* Infants whose parent(s) or guardian(s) provide informed consent to participate in the study.\n* Infants whose parent(s) or guardian(s) are willing to authorize data and specimen collection, storage and analysis.\n\nExclusion Criteria:\n\n* Infants born to a pregnant mother under 14 years of age (under Colombian law, pregnancies occurring in individuals younger than 14 years of age are legally presumed to result from sexual abuse).","29 Days",{"count":96,"type":22},1088,"5 Years","The goal of this observational study is to learn about the causes, severity, and long-term effects of respiratory tract infections (RTIs) in young children from birth to five years of age in Colombia and Panamá. The main questions it aims to answer are:\n\nHow often do respiratory infections occur in children under two years old, and which viruses or bacteria cause them? Why do some children develop more severe infections than others? Do early infections or vaccinations change how the immune system responds to future illnesses? How do viruses and bacteria interact in the respiratory tract to influence disease severity and long-term respiratory health? Researchers will follow newborns from birth until age five to understand how respiratory infections develop and affect children's health over time. Participants will not receive any experimental treatment.\n\nFamilies who join the study will:\n\nBe contacted twice a week through a phone app or phone calls to check for symptoms of respiratory infection.\n\nAttend in-person visits if their child becomes ill and every six months for routine follow-up.\n\nProvide nasal and blood samples during illness episodes so researchers can identify the viruses or bacteria causing infection and study how the immune system responds.\n\nThis study began in May 2024 and is being conducted in Cali, Colombia, and Panamá City, Panamá. The research team plans to continue to include participants and continue active follow-up until the children reach five years of age.\n\nThe information collected will help scientists and health professionals understand how different pathogens cause respiratory infections, what factors increase the risk of severe illness, and how early infections may influence long-term lung health. The study's findings will support future efforts to prevent and treat respiratory diseases in young children.",[100,101,27,102],"Respiratory Tract Infections (RTI)","Lower Respiratory Tract Infection (LRTI)","Cohort Study",[104,105,106],"Birth Cohort Study","Respiratory Tract Infection (RTI)","Children","2025-11-24",{"date":109,"type":45},"2025-11-25",{"date":111,"type":45},"2024-05-02",{"date":113,"type":22},"2031-12-30",{"name":115,"class":52},"Eduardo Lopez -Medina",2,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":53},"100595224","the-accredit-2-study-100595224","NCT07029672","The AcCREDiT 2 Study","Acute Respiratory Infections and Chronic Respiratory Disease Exacerbation Characterisation and Personalised Treatment Platform Study 2","ACCREDIT2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically suspected acute respiratory infection or exacerbation of chronic respiratory disease\n* Availability of respiratory tract sample\n\n  1. Spontaneously breathing patients are able to produce a sputum sample\n  2. Mechanically ventilated patients in intensive care are due to have an Bronchoalveolar lavage or non-directed bronchial lavage for a clinical indication\n* Due to receive either:\n\n  1. an anti-infective agent (e.g. antibiotic, antiviral or antifungal) OR\n  2. a systemic anti-inflammatory agent (e.g. corticosteroid)\n* Valid informed consent, assent or enrolment through deferred consent\n* Re-enrolment will be allowed if presenting for a separate acute event\n\nExclusion Criteria:\n\n* Alternate respiratory cause of presentation in the opinion of the treating physician (e.g. pulmonary embolism, heart failure, etc.)\n* High clinical likelihood of infection with a Hazard Group 3 pathogen (e.g. tuberculosis, anthrax, plague)",{"count":126,"type":22},120,"The ACCREDIT study - Acute respiratory infections and chronic respiratory disease exacerbations characterisation and personalised treatment platform study 2 (AcCREDiT 2).\n\nPatients with respiratory infections (such as pneumonia) or exacerbations of chronic respiratory conditions (such as emphysema) often require hospital admission. Infections or exacerbation are commonly caused by bacteria, viruses or fungi. In at least a quarter of patients no infectious cause of the exacerbation is found. Depending on the cause of the respiratory infections or exacerbations of chronic respiratory condition patients require prompt treatment with anti-infective drugs (antibiotics, anti-fungal or antiviral drugs) or anti-inflammatory drugs such as corticosteroids.\n\nPatients with respiratory infection or exacerbations of chronic respiratory conditions develop symptoms such as cough, sometimes with sputum, fever or breathlessness. These symptoms can be similar across several conditions, many of which are not due to infection (for example heart failure or blood clots in the lungs). When assessing patients with respiratory symptoms, clinicians face the challenge of limited information in the early stages of care as it takes three days to identify infectious organisms in the laboratory. Even when an infection is strongly suspected, distinguishing bacterial from viral or fungal infections on clinical grounds alone is difficult. This uncertainty often leads clinicians to prescribe a number of treatments, including antibiotics, before a clear diagnosis is made. Timely treatment is crucial for success and improved patient outcomes, especially for critically ill patients admitted to the intensive care unit (ICU). However, antibiotics may cause side effects, such as sickness and diarrhoea, and overuse of antibiotics leads to antibiotic resistance, making antibiotics less effective when they are really needed. Giving antibiotics to patients with an infection or exacerbation and avoiding antibiotics in patients without an infection requires rapid diagnostic tests. Furthermore, giving antibiotics prior to taking samples to diagnose infection can affect the sample being tested making it more likely to not give a useful result. For a diagnostic test for infection to be most useful it needs to be collected before an antibiotic is given - this is true for both clinical tests and those research tests which are clinical tests in development.\n\nModern technologies allow testing for an infection in hours rather than days. In order to understand how effective these technologies are, samples need to be taken from patients before they start treatment. In routine NHS care samples to test for infection should be taken before treatment has been started. However, in research studies samples are often taken up to a day after treatment has started which affects how effective the test is at finding infection. The forerunner to this study, called AcCREDiT, proposed investigating very rapid ways of identifying individuals with respiratory infection and exacerbation. However, the study team encountered challenges during the informed consent process, particularly with acutely unwell patients. Therefore, the AcCREDiT-2 was designed in collaboration with patients and public contributors to look at the feasibility of a modified informed consent process: verbal consent, assent for individuals with capacity to consent for themselves, and deferred consent.\n\nAcCREDiT-2 will be an observational study, meaning that no treatment will be changed, and no experimental drugs or tests used to influence the clinical care of participants. AcCREDiT-2 will also be a 'feasibility study', which is a smaller study designed to see what works well before embarking on a larger project. During the study the investigators will collect clinical information and samples, such as blood, sputum and stool, from patients who come to hospital with a presumed respiratory infection or exacerbation of their chronic respiratory condition. The investigators will compare new diagnostic tests to traditional laboratory tests to understand their relative advantages and disadvantages for patient care.\n\nThis is a 'feasibility' study, a small study ran first to make sure things work properly before expanding to a much larger study.",[129,130,33,28,27,131],"Chronic Respiratory Conditions","COPD","Respiratory Exacerbation",[133],"ACCREDIT","NOT_YET_RECRUITING","2025-07-01",{"date":137,"type":45},"2025-07-04",{"date":135,"type":22},{"date":140,"type":22},"2026-04",{"name":142,"class":143},"Manchester University NHS Foundation Trust","OTHER_GOV"]